Exegiline Pharma

Multifactorial Treatment of Alzheimer's Disease

Health Tech & Life Sciences
Active
Seed Yokne'am Illit, Israel Founded 2020
Last updated 2026-06-18
Total raised
—
Last: 2020-12
Stage
Seed
Founded
2020
Headcount
6
HQ
Yokne'am Illit, Israel
Sector
Health Tech & Life Sciences

About

Exegiline Pharma is developing a novel multifunctional oral drug, MT-031, for the treatment of dementia and Alzheimer's disease. MT-031's structure combines rivastigmine (Exelon) and rasagiline (Azilect) moieties and has the beneficial properties of both and more. It works as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A. MT-031 has a brain-permeable novel multifunctional MAO-AChE/BuChe inhibitor, anti-inflammatory properties, neuroprotective activity, and cognitive- and memory-enhancing activities. The molecule and its indications are protected by US and European patents. The company was established at Youdim Pharmaceuticals, a pharmaceutical company and incubator.

Funding history · 1 round · — total

2020-12

Q&A

What is Exegiline Pharma's primary focus?
Exegiline Pharma is focused on the multifactorial treatment of Alzheimer's Disease, developing a novel multifunctional oral drug called MT-031.
What is the mechanism of action for Exegiline Pharma's drug candidate MT-031?
MT-031 acts as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor, and also provides selective irreversible inhibition of MAO-A. It also exhibits anti-inflammatory, neuroprotective, and cognitive- and memory-enhancing activities.
When was Exegiline Pharma founded?
Exegiline Pharma was founded in December 2020.
How many employees does Exegiline Pharma currently have?
Exegiline Pharma has 1-10 employees.
Has Exegiline Pharma secured any patents for its technology?
Yes, Exegiline Pharma's molecule and its indications are protected by US and European patents.
Who are the founders of Exegiline Pharma?
The founders of Exegiline Pharma include Tal Youdim (Chairman), Dr. Santiago Ini (CEO), Prof. Moussa Youdim (Founder), and Prof. Eli Heldman (CSO, Director).
What is Exegiline Pharma's current stage of development?
Exegiline Pharma is currently in the Seed stage and its product is in the R&D stage.
Which investor participated in Exegiline Pharma's funding round in December 2020?
Youdim Pharmaceuticals participated in Exegiline Pharma's funding round in December 2020.

Team · 4

Tal Youdim
Founder · Chairman
LinkedIn ↗
Prof. Moussa Youdim
Founder · Founder
LinkedIn ↗
Prof. Eli Heldman
Founder · CSO, Director
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

drug-developmentparkinsonoral-drugspharma-companiesneurologybrain-disordertreatmentsdegenerative-diseasespharmaceuticalsalzheimers-disease
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2020-12
Employees (exact)6